ASX - By Stock
|
IMM |
Re:
Cytlimic, peptide vaccines and Imugene
|
|
Vivo
|
8 |
3.8K |
17 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
8
|
3.8K
|
17
|
|
ASX - By Stock
|
IMM |
Re:
Cytlimic, peptide vaccines and Imugene
|
|
Vivo
|
8 |
3.8K |
12 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
8
|
3.8K
|
12
|
|
ASX - By Stock
|
IMM |
Cytlimic, peptide vaccines and Imugene
|
|
Vivo
|
8 |
3.8K |
34 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
8
|
3.8K
|
34
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep AGM 2021 - CEO's Presentation
|
|
Vivo
|
6 |
3.2K |
16 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
6
|
3.2K
|
16
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
19 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
88
|
34K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
1 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
88
|
34K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
9 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
88
|
34K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
12 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
88
|
34K
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
9 |
24/11/21 |
24/11/21 |
ASX - By Stock
|
88
|
34K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
3 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
88
|
34K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
6 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
88
|
34K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
0 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
88
|
34K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
0 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
88
|
34K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
1 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
88
|
34K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
10 |
21/11/21 |
21/11/21 |
ASX - By Stock
|
88
|
34K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
15 |
20/11/21 |
20/11/21 |
ASX - By Stock
|
88
|
34K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
16 |
20/11/21 |
20/11/21 |
ASX - By Stock
|
88
|
34K
|
16
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
8 |
20/11/21 |
20/11/21 |
ASX - By Stock
|
88
|
34K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
13 |
20/11/21 |
20/11/21 |
ASX - By Stock
|
88
|
34K
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
6 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
88
|
34K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
7 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
88
|
34K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
8 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
88
|
34K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Phase II TACTI-002 trial recruitment successfully completed
|
|
Vivo
|
88 |
34K |
10 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
88
|
34K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
1 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
108
|
44K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Global Webcast Slides to Discuss Clinical Results
|
|
Vivo
|
22 |
9.9K |
19 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
22
|
9.9K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Global Webcast Slides to Discuss Clinical Results
|
|
Vivo
|
22 |
9.9K |
7 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
22
|
9.9K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Global Webcast Slides to Discuss Clinical Results
|
|
Vivo
|
22 |
9.9K |
8 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
22
|
9.9K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Global Webcast Slides to Discuss Clinical Results
|
|
Vivo
|
22 |
9.9K |
17 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
22
|
9.9K
|
17
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Change in substantial holding
|
|
Vivo
|
11 |
5.1K |
8 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
11
|
5.1K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Granted Chinese Patent For Eftilagimod Alpha A In Combination With A PD-1 Pathway...
|
|
Vivo
|
12 |
4.3K |
14 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
12
|
4.3K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
10 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
108
|
44K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
8 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
108
|
44K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
14 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
108
|
44K
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
15 |
13/11/21 |
13/11/21 |
ASX - By Stock
|
108
|
44K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
42 |
13/11/21 |
13/11/21 |
ASX - By Stock
|
108
|
44K
|
42
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
1 |
12/11/21 |
12/11/21 |
ASX - By Stock
|
108
|
44K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
7 |
12/11/21 |
12/11/21 |
ASX - By Stock
|
108
|
44K
|
7
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
4 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
108
|
44K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
19 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
108
|
44K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC
|
|
Vivo
|
108 |
44K |
24 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
108
|
44K
|
24
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
|
|
Vivo
|
88 |
35K |
0 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
88
|
35K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
|
|
Vivo
|
88 |
35K |
3 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
88
|
35K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
|
|
Vivo
|
88 |
35K |
0 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
88
|
35K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
|
|
Vivo
|
88 |
35K |
20 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
88
|
35K
|
20
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Vivo
|
213 |
89K |
1 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
213
|
89K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Vivo
|
213 |
89K |
4 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
213
|
89K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
|
|
Vivo
|
88 |
35K |
30 |
10/11/21 |
10/11/21 |
ASX - By Stock
|
88
|
35K
|
30
|
|
ASX - By Stock
|
IMM |
Re:
IMM CHART / SP
|
|
Vivo
|
213 |
89K |
10 |
09/11/21 |
09/11/21 |
ASX - By Stock
|
213
|
89K
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
743 |
339K |
12 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
743
|
339K
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
743 |
339K |
5 |
07/11/21 |
07/11/21 |
ASX - By Stock
|
743
|
339K
|
5
|
|